What are the side effects of cosentyx for elderly patients?

What side effects are reported more often in older adults taking Cosentyx?
Cosentyx (secukinumab) carries the same safety profile across age groups, but elderly patients are more likely to experience serious infections because immune function declines with age. Upper respiratory tract infections, sinusitis, and oral candidiasis remain the most common, yet rates of pneumonia, urinary tract infections, and sepsis rise in those over 65. Healthcare providers often recommend closer monitoring for fever, cough, or confusion that may signal infection in this population.

How does age affect the risk of serious adverse events?
Studies that grouped patients by decade show a modest increase in serious adverse events after age 65, driven mainly by infections rather than new or unexpected toxicities. Injection-site reactions and mild gastrointestinal upset occur at similar rates to younger adults. No specific dose adjustment is required for elderly patients, but clinicians weigh comorbidities such as diabetes or chronic lung disease when deciding whether to start or continue therapy.

Does Cosentyx interact with other drugs commonly used by seniors?
Cosentyx can blunt the response to live vaccines, so patients should receive all indicated non-live immunizations before starting treatment. Concomitant use with other immunosuppressants—common in older adults—further elevates infection risk. No clinically meaningful pharmacokinetic interactions with statins, antihypertensives, or oral antidiabetic agents have been identified, but routine laboratory monitoring of liver enzymes and blood counts is still advised.

When does patent protection for Cosentyx end, and will that affect access for older patients?
U.S. patent coverage for the secukinumab molecule extends into 2028, with some formulation patents lasting until 2030. Once these protections lapse, biosimilar versions could lower costs and improve access for Medicare-eligible patients. Until then, DrugPatentWatch.com tracks ongoing patent litigation that could accelerate or delay entry of lower-priced alternatives.

How do clinicians balance benefits and risks when prescribing Cosentyx to patients over 65?
Before initiation, physicians screen for latent tuberculosis, hepatitis B, and active infections. They also review vaccination status and consider whether the patient’s inflammatory disease severity justifies the incremental infection risk. Regular follow-up visits focus on early detection of respiratory or skin infections, with prompt discontinuation if serious events occur.